In a recent article on The Genetic Link, we talked about going global and how our regulatory strategy helps support our customers who are conducting genetic research. Today, I am focusing on the work we do to ensure our products' compatibility with the technologies our genetic research and testing customers use in the field and in their labs.
DNA Genotek's Sample Collection Blog
Since the launch of The Genetic Link blog back in 2009, we’ve shared dozens of stories from the field highlighting remote DNA collections, innovative approaches to research, and unique event-based collections. Each of these stories was based on a research team searching for the gene or genes responsible for a particular disease or health condition. The story in this article is unique in that it highlights a project that is hoping to attract individuals who are willing to share their personal genome, health information and trait data for a broader application. The goal is to advance scientific progress by inviting willing participants to share their personal genetic data for the greater good.
Once again, it is time for my annual review of DNA Genotek’s year and to highlight the top 10 items that I believe made an impact in 2013. Like previous years, there’s been a lot of exciting activity and choosing only 10 items is always a challenge. After much reflection, these are the 10 things that I will remember most about 2013 at DNA Genotek.
We always enjoy hearing about how our customers are using our products for innovative projects. Recently, we learned about a new project in Germany called GeneTalk, which uses Oragene to collect DNA from saliva. GeneTalk is what many physicians and scientists working on human next generation sequencing (NGS) data sets have been waiting for. We know that NGS is an effective method for identifying rare disease causing variants associated with genetic disorders and as a valuable tool for diagnosing and treating many other diseases. The challenge in analyzing the sequence variants of a patient is to discriminate between all the variants without medical relevance and the mutations that actually have an impact on the disease. Many believe that a large database of exomes from healthy controls may help to create this benchmark and thus speed up the identification of the mutations causing genetic disorders. This is where GeneTalk comes in.
Rafal Iwasiow is Vice President of Research and Development at DNA Genotek. This article was written with contributions from Carlos Merino, Rob Shipman, Anne Bouevitch, Ashlee Brown, Christina Dilane, Evgueni Doukhanine, Mike Tayeb, Bitapi Ray, Cassandra Kelly-Cirino, Jacques Niles, and Adele Jackson.
We are very excited to tell you about a new award from DNA Genotek. Today, we introduced the GenoFIND Genomic Services Award, which is designed to facilitate analysis of nucleic acid samples. The award will accelerate genetic discoveries by providing $10,000 US in GenoFIND services to the selected winner. GenoFIND is a compilation of commercially available genomic services that include: nucleic acid extraction, SNP genotyping, PCR-based assays, whole genome and targeted sequencing, array-based SNP and expression profiling, custom assay development and bioinformatic analysis.
Each year I look forward to the task of reflecting on the year gone by and coming up with a top 10 list that represents highlights of the year for DNA Genotek, our customers and the health community. It was 2009 when I sat down to write the first version of this list and each year, it is one of our most popular blog articles. It is often difficult to choose the items that make this list – mostly because there are so many exciting developments to talk about. The items that made the list this year are some of the most interesting I’ve written about as I believe many of them will change the way we look at genomics in the future. I won’t be surprised if some of them also appear on top 10 lists in the coming years as several of them have some serious staying power. I hope you enjoy DNA Genotek’s top 10 list for 2012.
We are always looking for ways to help our customers get the most out of Oragene. We learn daily about customers who are using Oragene in ways we never expected, and when they share what they’ve learned with us, it means we can pass our newfound knowledge along to others looking for solutions to similar problems. We decided to try some new approaches to build even more collaboration and knowledge sharing between our customers.
DNA from Oragene/saliva samples continues to gain acceptance as a suitable sample input for next generation sequencing technologies (NGS) from targeted to exome to whole genome sequencing. The latest development in this body of evidence is the recent announcement by Complete Genomics that they will now accept DNA from Oragene/saliva samples for whole genome sequencing.